The Fort Worth Press - VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street

USD -
AED 3.672503
AFN 66.000272
ALL 81.750267
AMD 377.657389
ANG 1.79008
AOA 916.497564
ARS 1447.743897
AUD 1.432295
AWG 1.80125
AZN 1.69884
BAM 1.656847
BBD 2.015105
BDT 122.260014
BGN 1.67937
BHD 0.377008
BIF 2953.091775
BMD 1
BND 1.272884
BOB 6.913553
BRL 5.245602
BSD 1.000479
BTN 90.561067
BWP 13.175651
BYN 2.857082
BYR 19600
BZD 2.012224
CAD 1.368345
CDF 2224.999981
CHF 0.77707
CLF 0.021813
CLP 861.249915
CNY 6.94215
CNH 6.938765
COP 3642
CRC 496.003592
CUC 1
CUP 26.5
CVE 93.41048
CZK 20.61185
DJF 178.163135
DKK 6.32984
DOP 63.04994
DZD 130.013823
EGP 46.974985
ERN 15
ETB 154.976835
EUR 0.847765
FJD 2.206601
FKP 0.732184
GBP 0.73708
GEL 2.690395
GGP 0.732184
GHS 10.985781
GIP 0.732184
GMD 73.514885
GNF 8780.996111
GTQ 7.67429
GYD 209.32114
HKD 7.81233
HNL 26.428662
HRK 6.385504
HTG 131.143652
HUF 321.765975
IDR 16870
ILS 3.106995
IMP 0.732184
INR 90.323502
IQD 1310.5
IRR 42125.000158
ISK 122.77015
JEP 0.732184
JMD 156.862745
JOD 0.709032
JPY 157.190173
KES 128.999889
KGS 87.449732
KHR 4030.000237
KMF 416.999971
KPW 900.030004
KRW 1465.559807
KWD 0.30735
KYD 0.83376
KZT 497.113352
LAK 21520.880015
LBP 86150.000117
LKR 309.665505
LRD 185.999893
LSL 16.060215
LTL 2.95274
LVL 0.60489
LYD 6.323093
MAD 9.174502
MDL 16.928505
MGA 4431.457248
MKD 52.26893
MMK 2099.783213
MNT 3569.156954
MOP 8.051354
MRU 39.72959
MUR 46.060083
MVR 15.460281
MWK 1737.9996
MXN 17.35351
MYR 3.946989
MZN 63.759989
NAD 16.060109
NGN 1370.429432
NIO 36.81834
NOK 9.68341
NPR 144.897432
NZD 1.668235
OMR 0.384501
PAB 1.000479
PEN 3.362501
PGK 4.286719
PHP 58.717498
PKR 279.84277
PLN 3.574895
PYG 6622.13506
QAR 3.64125
RON 4.319497
RSD 99.522041
RUB 76.547406
RWF 1459.958497
SAR 3.750074
SBD 8.064647
SCR 13.682273
SDG 601.50319
SEK 9.005105
SGD 1.27355
SHP 0.750259
SLE 24.550125
SLL 20969.499267
SOS 571.495602
SRD 37.894002
STD 20697.981008
STN 20.755852
SVC 8.7544
SYP 11059.574895
SZL 16.060401
THB 31.744501
TJS 9.349774
TMT 3.505
TND 2.845497
TOP 2.40776
TRY 43.54031
TTD 6.777163
TWD 31.683899
TZS 2575.000201
UAH 43.151654
UGX 3562.246121
UYU 38.562056
UZS 12264.970117
VES 377.98435
VND 25970
VUV 119.687673
WST 2.726344
XAF 555.589718
XAG 0.012796
XAU 0.000206
XCD 2.70255
XCG 1.803149
XDR 0.691101
XOF 555.690911
XPF 101.550161
YER 238.325012
ZAR 16.154095
ZMK 9001.179364
ZMW 19.585153
ZWL 321.999592
  • RBGPF

    0.1000

    82.5

    +0.12%

  • SCS

    0.0200

    16.14

    +0.12%

  • BCC

    0.2800

    90.51

    +0.31%

  • GSK

    1.8800

    59.11

    +3.18%

  • RIO

    -3.1700

    93.31

    -3.4%

  • CMSD

    -0.0100

    23.86

    -0.04%

  • RYCEF

    -0.0600

    16.62

    -0.36%

  • CMSC

    0.0800

    23.6

    +0.34%

  • BCE

    -0.9550

    25.385

    -3.76%

  • NGG

    -1.1700

    86.62

    -1.35%

  • AZN

    2.5350

    189.985

    +1.33%

  • JRI

    0.1450

    13.295

    +1.09%

  • VOD

    -0.9250

    14.785

    -6.26%

  • BTI

    0.4650

    62.095

    +0.75%

  • RELX

    0.7350

    30.515

    +2.41%

  • BP

    -0.8550

    38.345

    -2.23%

VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street
VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street

VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street

Twelve months of national and global coverage to include long-form interviews, earned media, television commercials, iconic outdoor billboards, and accredited investor events

Text size:

NEW YORK CITY, NEW YORK / ACCESS Newswire / February 5, 2026 / Vivos Therapeutics, Inc. (NASDAQ:VVOS), a medical technology company focused on innovative solutions for breathing and sleep disorders, today announced that it has entered into a 12-part media series agreement with New to The Street, one of the longest-running business television and digital media platforms serving public companies in the U.S. and international markets.

The 12-month series is designed to expand Vivos Therapeutics' visibility among investors, healthcare professionals, and strategic partners through a comprehensive, multi-channel media strategy spanning linear television, digital platforms, social media, outdoor advertising, and live investor engagement.

As part of the agreement, Vivos Therapeutics will receive:

Long-form broadcast interviews distributed nationally and internationally

Earned media coverage supporting corporate milestones and clinical positioning

Television commercials airing as sponsored programming alongside New to The Street broadcasts

Iconic outdoor billboard placements in high-impact financial and metropolitan locations

Accredited investor events, providing direct engagement with screened, invitation-only investor audiences

The series will allow Vivos Therapeutics to consistently communicate its clinical progress, commercial execution, and long-term growth strategy throughout the year.

"Partnering with New to The Street provides a sustained, credible platform to communicate our story to a broad audience of investors and stakeholders," said a spokesperson for Vivos Therapeutics. "This multi-part series supports our commitment to education, transparency, and long-term shareholder engagement."

The first segment in the Vivos Therapeutics series is expected to begin airing in the coming weeks, with coverage continuing throughout the 12-month term.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (NASDAQ:VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment solutions for breathing and sleep disorders arising from certain dentofacial abnormalities, including obstructive sleep apnea (OSA) and snoring in adults and children.

Vivos' proprietary technologies have been cleared by the U.S. Food and Drug Administration (FDA) for use in adult patients diagnosed with all severity levels of OSA, as well as moderate-to-severe OSA in pediatric patients ages 6 to 17. The company's groundbreaking Complete Airway Repositioning and Expansion (CARE) devices represent the only FDA 510(k)-cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate-to-severe OSA in children.

OSA affects more than one billion people worldwide, with an estimated 80% or more remaining undiagnosed. Beyond disrupted sleep, OSA is closely linked to numerous serious chronic health conditions. While legacy treatments such as CPAP have addressed symptoms, they are often mechanistic and may not address the underlying anatomical causes of the disorder.

Founded in 2016 and headquartered in Littleton, Colorado, Vivos is working to transform the standard of care for sleep-disordered breathing through innovative technology, education, and strategic collaborations with sleep healthcare providers. The company's comprehensive approach-known as The Vivos Method-offers a proprietary, clinically effective, nonsurgical, noninvasive, and nonpharmaceutical solution, designed to address the root causes of OSA and improve long-term patient outcomes.

For more information, visit www.vivos.com.

About New to The Street

New to The Street is a 17-year-old, nationally and internationally syndicated business television brand that broadcasts weekly on Bloomberg Television as sponsored programming, featuring client interviews and television commercials. The program airs across the United States, MENA (Middle East & North Africa), and Latin America, delivering consistent global exposure.

In addition to its linear television distribution, New to The Street operates one of the largest YouTube subscriber channels in the financial and business media space, with over 4.4 million subscribers on New to The Street TV. The platform combines long-form interviews, earned media, digital amplification, and iconic outdoor advertising to deliver predictable, high-impact visibility for its clients.

https://youtube.com/@newtothestreettv

Media Contact:
Monica Brennan
New to The Street
[email protected]

SOURCE: New to The Street



View the original press release on ACCESS Newswire

G.Dominguez--TFWP